Percutaneous electrical stimulation is effective in reducing chronic knee pain and improving functionality in affected patients.

Crisugabalin provides significant improvement in average daily pain score and shows promise as a postherpetic neuralgia treatment.

They enrolled patients with knee osteoarthritis from 2 Phase 2 and 2 Phase 3 trials with Kellgren-Lawrence (KL) Grades 2–3 ...

Merck KGaA (MKGAY.PK), a German science and technology major, announced that the Phase III MANEUVER trial of pimicotinib, an ...

Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that the Phase III MANEUVER trial ...

Abbisko announces positive results from phase 3 MANEUVER study of pimicotinib to treat tenosynovial giant cell tumour: Shanghai Wednesday, November 13, 2024, 18:00 Hrs [IST] Abbis ...

including stiffness by Numeric Rating Scale (NRS; -3.00 mean change from baseline versus -0.57 for placebo, p<0.0001) and ...

and 60 minutes using a standardized numeric pain scale (0 = no pain, 10 = worst pain possible). At 30 minutes, reductions in pain were similar in the two groups. Both groups had further pain ...

Nipocalimab was granted U.S. FDA Breakthrough Therapy Designation for the treatment of adults living with moderate-to-severe Sjögren's disease based on results from the Phase 2 DAHLIAS study ...

Spring House, Massachusetts Wednesday, November 13, 2024, 14:00 Hrs [IST] ...